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ABSTRACT
Neurofibromatosis type 1 (NF1; MIM# 162200) is a familial cancer syndrome that 
affects 1 in 3,500 individuals worldwide and is inherited in an autosomal dominant 
fashion. Malignant Peripheral Nerve Sheath Tumors (MPNSTs) represent a significant 
cause of morbidity and mortality in NF1 and currently there is no treatment or definite 
prognostic biomarkers for these tumors. Telomere shortening has been documented 
in numerous tumor types. Short dysfunctional telomeres are capable of fusion and it 
is considered that the ensuing genomic instability may facilitate clonal evolution and 
the progression to malignancy. To evaluate the potential role of telomere dysfunction 
in NF1-associated tumors, we undertook a comparative analysis of telomere length 
in samples derived from 10 cutaneous and 10 diffused plexiform neurofibromas, and 
19 MPNSTs. Telomere length was determined using high-resolution Single Telomere 
Length Analysis (STELA). The mean Xp/Yp telomere length detected in MPNSTs, at 
3.282 kb, was significantly shorter than that observed in both plexiform neurofibromas 
(5.793 kb; [p = 0.0006]) and cutaneous neurofibromas (6.141 kb; [p = 0.0007]). The 
telomere length distributions of MPNSTs were within the length-ranges in which 
telomere fusion is detected and that confer a poor prognosis in other tumor types. 
These data indicate that telomere length may play a role in driving genomic instability 
and clonal progression in NF1-associated MPNSTs.
INTRODUCTION
Neurofibromatosis type 1 (NF1; MIM# 162200) 
is a familial cancer syndrome that affects 1 in 3,500 
individuals worldwide, it is inherited in an autosomal 
dominant fashion and is caused by inactivation of the NF1 
tumor suppressor gene, located at 17q11.2. NF1 patients 
develop a variety of tumor types, including cutaneous 
neurofibromas, plexiform neurofibromas, malignant 
peripheral nerve sheath tumors, (MPNSTs), optic gliomas, 
phaechromocytomas, glomus tumors, gastrointestinal 
tumors and leukaemia [1]. While homozygous inactivation 
of the NF1 gene occurs in both the benign cutaneous 
and plexiform neurofibromas, as well as in MPNSTs, 
additional genetic, biochemical and cellular changes are 
clearly required for malignant transformation to occur 
in MPNSTs. Indeed, such tumors represent a significant 
cause of morbidity and mortality in NF1, with patients 
exhibiting an 8-13% lifetime risk of developing an 
MPNST, often developing within a pre-existing plexiform 
neurofibroma, an atypical neurofibroma or a focal 
subcutaneous neurofibroma [2,3,4]. More than half of all 
MPNSTs diagnosed are found in association with NF1, 
with such patients usually exhibiting a poor prognosis in 
comparison to patients with a sporadic MPNST [5].
The presence of internal plexiform neurofibromas 
is strongly associated with MPNST development [6], 
with a high benign tumor burden also representing a risk 
factor for the development of MPNST. Other risk factors 
for the development of MPNST include the presence 
of an inherited gross deletion of the entire NF1 gene 
region in 17q11.2 [7], previous radiation therapy [7], the 
presence of neurofibromatous neuropathy [8], as well as 
a family history of MPNSTs [9]. Unfortunately, many 
MPNSTs at first presentation, are already past surgical 
intervention as the diagnosed tumor has reached a late 
stage of development, with metastases commonly in the 
lungs, but also in the liver and brain. Thus, the 5-and 10-
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year survival rates for such affected NF1 individuals are 
only 20%–50% and 7.5%, respectively. While there are 
no effective treatments for MPNSTs, complete surgical 
excision with clear margins, if possible, is the therapy of 
choice, with chemotherapy and radiotherapy also being 
employed despite its limited effectiveness.
Several studies have analyzed aspects of tumor 
DNA, RNA and proteins in the search for potential 
molecular signatures capable of differentiating between 
aggressive MPNSTs and benign neurofibromas [10-21]. 
We have previously shown, using different DNA array 
platforms that MPNSTs are associated with multiple 
gross DNA rearrangements, with both large deletions and 
amplifications observed [11, 12, 15]. Recently, whole-
genome/exome sequencing analyses have revealed 
recurrent additional genetic alterations consisting of 
somatic loss-of-function mutations or deletions of the 
Polycomb repressive complex 2 (PRC2) subunits (EED or 
SUZ12) in the vast majority of sporadic, NF1-associated, 
and radiotherapy-associated MPNSTs [19, 20, 21]. 
From these data it is clear that MPNST development is 
a complex molecular genetic process in which multiple 
mutations of many genes, all contributing to deregulation 
of multiple signaling and regulatory pathways, is to be 
expected. 
Early detection of MPNSTs would greatly facilitate 
the identification and clinical management of these 
affected NF1 patients, however despite numerous studies 
no definitive information on diagnostic and prognostic 
biomarkers associated with MPNST development is yet 
available [15, 17, 18]. Telomeres are structures that cap 
the ends of eukaryotic chromosome protecting the natural 
chromosome-end from recognition by the cellular DNA 
damage response [22]. Telomere shortening with on-going 
cell division leads to the uncapping of the telomere and the 
initiation of a Tp53 dependent G1-S cell-cycle arrest, that 
provides a limit on replicative lifespan [23]. However, in 
the absence of a fully functional DNA damage checkpoint 
response, short dysfunctional telomeres can be subjected 
to DNA repair activities that result in the fusion of 
telomeres with other telomeric or non-telomeric loci 
[24]; the resulting di-centric chromosomes initiate cycles 
of anaphase-bridging, breakage and fusion that lead to 
large-scale genomic rearrangements of the kind observed 
in many tumor types [25]. Telomere length has recently 
emerged as a powerful prognostic and predictive marker 
in several tumor types, including chronic lymphocytic 
leukemia (CLL) [26, 27) and breast cancer [28]. Our 
previous studies [29] identified increased telomerase 
activity in high grade MPNSTs but was not detectable 
in diffused plexiform neurofibromas or cutaneous 
neurofibromas, consistent with a role for telomere 
dysfunction during the progression of malignancy. In this 
study we have focused on the possible role that telomere 
length may play in NF1 tumorigenesis and to evaluate the 
potential of high-resolution telomere length analysis as a 
diagnostic and prognostic tool.
RESULTS
The telomere length distributions at XpYp were 
determined using STELA in 19 MPNSTs, 10 plexiform 
neurofibromas and 10 cutaneous neurofibromas (Fig. 
1A and supplementary figure). It was apparent from this 
analysis that the telomere length distributions of MPNSTs 
were distinct from those observed in both the plexiform 
and the cutaneous neurofibromas. The telomere lengths 
of 5 MPNSTs displayed clear bi-modal distributions; see 
for example, tumors 2 and 4 shown in Figure 1A. These 
telomere length distributions are consistent with the 
presence of either multiple clones within the same tumor, 
or the presence of normal somatic tissue within the sample. 
These two possibilities could not be formally distinguished 
and because our previous data from other tumor types [28, 
30] show that tumors displaying shorter telomeres display 
a more aggressive phenotype, we used the mean of the 
lower telomere length distribution for these 5 tumors that 
exhibited a bimodal telomere length distribution. Overall 
the mean Xp/Yp telomere length detected in MPNSTs, 
was 3.282kb and this was significantly shorter than that 
observed in both plexiform neurofibromas (5.793 kb; 
[p == 0.0006] and cutaneous neurofibromas (6.141 kb; 
[p=0.0007]) (Figure 1B). The telomere length profiles 
observed in plexiform neurofibromas and cutaneous 
neurofibromas were indistinguishable [p=0.63]. The 
telomere erosion observed in MPNSTs was extensive, 
with 15 of the 19 samples (79%), displaying mean 
telomere length distributions that were less than the 3.81 
kb telomere length threshold below which telomere fusion 
is detected and that confers a poor prognosis in both CLL 
and breast cancer [Figure 1B, 26, 28].
Using a variety of microarray platforms, we and 
others [10-15,5], have previously shown that DNA 
from MPNSTs exhibits significant large-scale genomic 
rearrangements, with both extensive DNA deletions 
and amplifications, and that these tumors also show 
significantly elevated levels of telomerase [29]. Owing 
to the limited data on samples used for telomere length 
profiles, we are unable to comment whether MPNSTs 
undergoing a period of genomic instability are driven by 
telomere dysfunction. A comparison between the telomere 
size and the genomic data derived from 13 MPNSTs from 
previous studies is shown in Table 1.
DISCUSSION
This study, the first to investigate the possible role of 
telomere length in the aetiology of NF1-associated tumors, 
indicates that high-resolution telomere length analysis 
could be important in understanding the molecular 
pathology of MPNSTs.
We have previously shown that the telomerase 
levels are elevated in MPNSTS compared to either benign 
cutaneous or plexiform neurofibromas [29]. To explore 
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Figure 1: Telomere length distributions of MPNSTs are distinct from those observed in plexiform and cutaneous 
neurofibromas. A., example of XpYp STELA in 4 MPNSTs, 4 plexiform neurofibromas and 5 cutaneous neurofibromas. Mean telomere 
length and standard deviation are detailed below the gel image and indicated with a red on the gel image. For tumors that displayed a clear 
bimodal distribution the mean of lower modal distribution was calculated. B., scatter plot depicting mean XpYp telomere length in the 
three different tumor types as indicated below. The 3.81 kb telomere fusion threshold, previously defined in CLL (26) is depicted in blue.
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whether there was a potential correlation between telomere 
length and telomerase expression, we used the telomerase 
data available for MPNST 1, 2, 4, 5, 6 and 8 included in 
this study [29]. Interestingly, telomerase expression was 
observed in all tumors except for MPNST 8, which also 
revealed a long telomere. There is therefore no obvious 
relationship between telomere length and telomerase 
activity in MPNSTs, which is consistent with the general 
observations that the apparent up-regulation of telomerase 
activity and the presence of shorter telomeres in the 
majority of tumors [33, 34]. Instead we view the presence 
of telomerase activity and short telomeres as a marker of 
a tumor that has transited a telomere driven crisis, that 
leads to large-scale genomic rearrangements and the up-
regulation of telomerase activity [24].
It is already known that shortened telomeres play 
an important role in tumorigenesis in many malignancies 
[35], including non-small cell lung cancer [36], colorectal 
Table 1: Genomic Data on 13 NF1-associated MPNSTs.
 NF1 Mutations  Target Array
ID Grade Telomere Length NF1 Germline NF1 Somatic p53 Mutations Telomerase Deleted Amplified
1 High Short c2002-14C>G LOH: I12b, IVS27, EVI20, IVS38, 3’NF, Del Array CGH LOH Positive
HMMR, MMP13, mTOR, 
NF1, OSF2, p16-INK4a, 
PTCH2, RB1, TP53
CCNE2, 
SOX10, 
TOP2A
2 High Short Exon 2,3 Del
LOH: Ex5, I12b, IVS27, 
EVI20, IVS38, C&CT, EW206, 
EW207, 3’NF1;>2.2 Mb Del 
Array CGH
LOH Positive
BLBP, HMMR, HSPCA, 
Mki-67, MMP13, NF1, 
p16-INK4a, PTEN, TP53
BIRC5, 
CCND1, 
EGFR, 
ITGB4, 
TERT, 
TOP2A
3 Low Short c2497_2497delT,S8 33fsX8 Del Exon 1-4c, 6 No Not Done NF1, TOP2A FOXA2
4 High Long Not Found c5788_5788delC No Positive NF1
CCND1, 
ITGB4, 
MMP9, 
PTCH2, 
SOX10, 
TERT, TP73, 
TSC2
5 High Short c3457_3460delCTC A, L1153fsX4 LOH -3’NF1: Del Array CGH LOH Positive
EPHA7, FN1, HMMR, 
Mki-67, MMP13, NF1, 
p16-INK4a, RB1
BIRC5, 
ITGB4, TERT
6 High Short c5234 C>G , S1745X LOH: HHH202, I12b, IVS27, EW206 LOH Positive
HMMR, HSPCA, 
LICAM2, MMP13, NF1, 
RASSF2
mTOR
7 High Long c5234 C>G , S1745X Partial Gene Deletion - Array CGH No inconclusive No Changes No Changes
8 Low Long c1318C>T, R440X LOH: HHH202, EVI20. IVS38 LOH Negative BLBP, EPHA7, Mki-67, MMP13, RASSF2 TOP2A
9 High Short Whole Gene Deletion  LOH Not Done   
10 Low Long?    Not Done   
11 High Short     
HGF, HMMR, HSPCA, 
LICAM2, MET, NF1, 
OSF2, p16-INK4a, 
RASSF2, RB1
EGFR, 
ITGB4, 
MMP9
12 Unknown Short     MMP13, NF1, RASSF2, TP53
BIRC5, 
CCNE2, 
CCND1, 
EGFR, FLT4, 
FOXA2, 
HGF, 
HSPCA, 
ITGB4, 
MDM4, 
MET, mTOR, 
PDGFRA, 
S108, TERT, 
TOP2A, TP73
13 Unknown Short     
BLBP, HMMR, MMP13, 
NF1, OSF2, p16-INK4a, 
RB1
CDKN18/
p28, FLT4, 
FOXM1, 
RASSF2
Genomic data included in this Table has been taken from previous published reports: [3,11,12,15,31,32] 
LOH - Loss of heterozygosity identified either with  intragenic markers or by array CGH
CGH - Comparative Genomic Hybridisation
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cancer [37], prostate cancer [38], chronic lymphocytic 
leukemia [30], breast cancer [39], ovarian cancer [40], 
and several others. Our data show that the 79% of the 
MPNSTs analyzed displayed telomere length distributions 
within the length ranges at which telomere fusion is 
detected in CLL [26]. Stratification of CLL and Breast 
cancer patient cohorts based on these telomere length 
ranges provide powerful prognostic information [26, 28] 
and it is therefore possible that high-resolution telomere 
length analysis may also provide prognostic information 
in MPNSTs. Functional sequence variation in a number 
of genes involved in telomere maintenance have also been 
investigated in genetic association studies of common 
disease and cancer. Sequence variants located within, 
or immediately adjacent to the TERT gene, are strongly 
associated with several cancers, notably melanoma, breast, 
bladder and prostate cancers [41]. Several such TERT 
promoter mutations, that significantly increase telomerase 
expression, have been identified in melanomas and several 
other tumors. However, detailed sequence analysis of the 
TERT promoter in 96 MPNSTs found that <10% showed 
a specific C228T alteration in the TERT promoter [42], 
and these tumors were all sporadic (non-NF1-related 
MPNSTs). Hence, in contrast to other neuroectodermal 
derived malignant neoplasms, TERT promoter mutations 
occur infrequently in MPNST.
MPNSTs, like other tumors, are often extremely 
heterogeneous, both at the cellular and molecular 
levels [43,44]. Indeed, we have shown that more than 
three-quarters of all MPNSTs display a degree of intra-
tumoral molecular heterogeneity, as evidenced from the 
differences in the loss-of-heterozygosity (LOH) levels 
found in different regions of the same tumor [43]. The 
significant molecular heterogeneity evident at many 
different gene loci in this study clearly indicates the need 
to be able to integrate both molecular and morphological 
biomarkers in early MPNST diagnosis. The bimodal 
distribution of telomere length observed in different 
MPNSTs found in this present study, further reflects this 
genetic and cellular heterogeneity. The heterogeneity of 
telomere length profiles can reflect the clonal composition 
of the sample analysed, however we consider that the 
clear bimodal distributions observed in MPNSTs is more 
likely a function of purity of the sample ie the presence of 
both tumor and normal tissue, this cellular and molecular 
heterogeneity has been reported.
Many human cancers exhibit shortened telomeres 
and this is consistent with the increased cell division often 
observed during tumor progression. Telomere fusion and 
genomic instability, usually related to tumor progression, 
has been found in several tumor types [26,37,45]. The 
MPNSTs found to harbor short telomeres in this study, 
were already known to exhibit large-scale genomic 
rearrangements (Table1) [11, 12, 15], a feature absent 
from other benign cutaneous and plexiform neurofibromas 
tumors, which predominantly show long telomeres. Such 
genomic instability is found in human breast cancers, 
where short telomeres are implicated in the progression 
from benign ductal carcinoma to malignant ductal 
carcinoma [46,47,28], and are also observed in several 
hematological cancers [48].
Genomic alterations to many other chromosomal 
regions have been reported in NF1-MPNSTs. Such 
alterations often involve the cell cycle genes TP53, 
CDKN2A and RB [1,49], with frequent deletions of 
the 9p21 region containing the CDKN2A (p16) (50-
53). Frequent loss of the 17p13 region, encompassing 
the TP53 gene, has also been found in NF1-MPNSTs 
[54,55], soft tissue sarcomas and other cancers [56,57]. 
Furthermore, aberrant expression of several proteins of 
the Rb pathway has been found in soft tissue sarcomas, 
including MPNSTs [53]. In the present study 5/9 MPNSTs 
with shortened telomeres also exhibited LOH at the TP53 
locus (Table 1). Based on our small dataset it is difficult 
to provide definitive correlations in NF1-associated 
MPNSTs between short telomeres and large-scale genomic 
instability. However, these observations are consistent 
with the hypothesis that telomere dysfunction during the 
progression of MPNSTs, but not plexiform neurofibromas 
or cutaneous neurofibromas, may drive large-scale genome 
instability and acquisition of specific genomic mutations 
that facilitate progression. Clearly further analysis is 
required to assess the full extent of telomere dysfunction 
and fusion in these tumors and to assess the prognostic 
and predictive potential of high-resolution telomere length 
analysis.
MATERIALS AND METHODS
19 macrodissected MPNSTs were obtained from 
19 unrelated patients, in addition 10 diffused plexiform 
and 10 cutaneous neurofibromas were also taken from 
20 unrelated NF1 patients. The samples used in this 
study were provided by genetic centers in Cardiff 
(UK), London (UK), Toronto (Canada) and Hamburg 
(Germany). The MPNSTs were classified in accordance 
with the WHO classification scheme [58] and FNCLCC 
(French Federation Nationale des Centres de Lutte Contre 
le Cancer system). Reports on MPNSTs included in this 
study have previously been published although in order 
to maintain confidentiality, the identity of tumors is coded 
[11,12,15, 29, 31, 32]. DNA was extracted from fresh 
frozen tissue as previously reported [11] and analyzed 
using Single Telomere Length Analysis (STELA) [59]. 
This project received the full approval of the local Ethics 
committee. Tumor DNA was extracted and the STELA 
reactions at the Xp/Yp telomeres were carried out as 
previously described [30]. Following DNA quantification 
(in triplicate) by Hoechst 33258 fluorometry (BioRad, 
Hemel Hempstead, UK), the genomic DNA was initially 
diluted to 10 ng/µl in 10 mM Tris-HCl (pH 7.5) and then 
further diluted to 250 pg/µl in a volume of 40 µl that 
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contained 1 µM Telorette2 linker and 1 mM Tris-HCl (pH 
7.5). Multiple PCRs were carried out for each test DNA in 
10 µl volumes, containing 250 pg of diluted DNA, 0.5 µM 
of the telomere-adjacent and Teltail primers, 75 mM Tris-
HCl (pH 8.8), 20 mM (NH4)
2
SO4, 0.01% Tween-20, 1.5 
mM MgCl
2
, and 0.5 U of a 10:1 mixture of Taq (ABGene, 
Epsom, UK) and Pwo polymerase (Roche Diagnostics, 
West Sussex, UK). The reactions were cycled with an 
MJ PTC-225 thermocycler as described previously [30]. 
The DNA fragments were resolved by 0.5% TAE agarose 
gel electrophoresis, and detected Southern hybridisation 
with a random-primed [α-33P] labelled (PerkinElmer, 
Coventry, UK) telomere repeat containing probe together 
with a probe to detect the 1 kb (Stratagene, La Jolla, 
CA, USA) and 2.5 kb (BioRad, Hemel Hempstead, UK) 
molecular weight markers. The hybridised fragments 
were detected by phosphorimaging with a Typhoon FLA 
9500 phosphorimager (GE Healthcare, St Giles, UK). The 
molecular weights of the DNA fragments were calculated 
using the Phoretix 1D quantifier (Nonlinear Dynamics, 
Newcastle-upon-Tyne, UK).
Statistical comparisons were made using the 
nonparametric Mann Whitney tests (Prism 6).
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